Positive correlation between estradiol and vascular endothelial growth factor but not fibroblast growth factor-2 in normal human breast tissue in vivo

被引:48
作者
Dabrosin, C [1 ]
机构
[1] Linkoping Univ Hosp, Fac Hlth Sci, Div Gynecol Oncol, S-58185 Linkoping, Sweden
关键词
D O I
10.1158/1078-0432.CCR-05-0977
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Angiogenesis is crucial in tumor development and progression. Ovarian hormones regulate angiogenesis in the reproductive tract but very little is known about its regulation in the normal breast. Sex steroids play an important role in breast cancer development by poorly understood mechanisms. Vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2) are potent stimulators of angiogenesis. Both VEGF and FGF-2 function in autocrine/ paracrine pathways and there is a major contribution of bioactive proteins by a posttranslational activation of sequestered molecules in the extracellular space. A direct measurement of these molecules in the extracellular compartment is, therefore, needed. Experimental Design: In this study, microdialysis was used to measure extracellular VEGF and FGF-2 in normal human breast tissue in situ in 11 premenopausal and 5 postmenopausal women. Results: Significantly higher level of VEGF in breast tissue of premenopausal women was found. Plasma as well as local estradiol and breast tissueVEGF exhibited significant correlations, whereas progesterone had no correlation with breast VEGF. FGF-2 did not correlate with either estradiol or progesterone. Conclusion: The result suggests that estradiol is a more potent regulator of freeVEGF levels than progesterone in the normal breast. The control of free FGF-2 seems to be independent of sex steroids in the breast. Estrogen induction of free extracellular VEGF may be one mechanism involved in sex steroid - dependent breast carcinogenesis.
引用
收藏
页码:8036 / 8041
页数:6
相关论文
共 33 条
[1]  
Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0
[2]  
Beral Valerie, 2003, Lancet, V362, P419, DOI 10.1016/S0140-6736(03)14065-2
[3]   FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition [J].
Cross, MJ ;
Claesson-Welsh, L .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (04) :201-207
[4]   Variability of glutathione during the menstrual cycle-due to estrogen effects on hepatocytes? [J].
Dabrosin, C ;
Öllinger, K .
FREE RADICAL BIOLOGY AND MEDICINE, 2004, 36 (02) :145-151
[5]   Estradiol increases extracellular levels of vascular endothelial growth factor in vivo in murine mammary cancer [J].
Dabrosin, C ;
Margetts, PJ ;
Gauldie, J .
INTERNATIONAL JOURNAL OF CANCER, 2003, 107 (04) :535-540
[6]   Increase of free insulin-like growth factor-1 in normal human breast in vivo late in the menstrual cycle [J].
Dabrosin, C .
BREAST CANCER RESEARCH AND TREATMENT, 2003, 80 (02) :193-198
[7]   Variability of vascular endothelial growth factor in normal human breast tissue in vivo during the menstrual cycle [J].
Dabrosin, C .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (06) :2695-2698
[8]   Estradiol promotes growth and angiogenesis in polyoma middle T transgenic mouse mammary tumor explants [J].
Dabrosin, C ;
Palmer, K ;
Muller, WJ ;
Gauldie, J .
BREAST CANCER RESEARCH AND TREATMENT, 2003, 78 (01) :1-6
[9]   Technical aspects of microdialysis of human breast [J].
Dabrosin, C .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2001, 61 (04) :269-272
[10]   Variability of glutathione levels in normal breast tissue and subcutaneous fat during the menstrual cycle: An in vivo study with microdialysis technique [J].
Dabrosin, C ;
Ollinger, K ;
Ungerstedt, U ;
Hammar, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (05) :1382-1384